Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.2% |
| 2 | Technology | 14.19% |
| 3 | Financials | 12.33% |
| 4 | Consumer Staples | 10.22% |
| 5 | Industrials | 9.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
KANG
2301
DELISTED
iKang Healthcare Group, Inc.
KANG
| $1.84M | ﹤0.01% |
150,240
+120,740
| +409% | +$1.75M |
|
|
INFI
2302
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $1.84M | ﹤0.01% |
1,169,873
-269,368
| -19% | -$520K |
|
2303
Cheniere Energy
CQP
$33.3B
| $1.83M | ﹤0.01% |
+56,600
| New | +$1.81M |
|
2304
State Street Utilities Select Sector SPDR ETF
XLU
$23B
| $1.83M | ﹤0.01% |
70,600
-20,800
| -23% | -$546K |
|
2305
Peoples Financial Services
PFIS
$714M
| $1.83M | ﹤0.01% |
41,800
-4,200
| -9% | -$178K |
|
2306
BlueLinx
BXC
$679M
| $1.82M | ﹤0.01% |
166,360
+62,400
| +60% | +$620K |
|
|
AVNS
2307
DELISTED
Avanos Medical
AVNS
| $1.82M | ﹤0.01% |
46,300
+27,221
| +143% | +$1.03M |
|
2308
Silvercrest Asset Management
SAMG
$77.8M
| $1.81M | ﹤0.01% |
134,698
+698
| +0.5% | +$9.1K |
|
|
REV
2309
DELISTED
Revlon, Inc.
REV
| $1.81M | ﹤0.01% |
76,259
-114,800
| -60% | -$2.61M |
|
|
CBAY
2310
DELISTED
Cymabay Therapeutics
CBAY
| $1.8M | ﹤0.01% |
313,392
+81,443
| +35% | +$347K |
|
2311
Monro
MNRO
$355M
| $1.8M | ﹤0.01% |
+43,206
| New | +$2.15M |
|
2312
Alico
ALCO
$303M
| $1.8M | ﹤0.01% |
57,591
-4,100
| -7% | -$123K |
|
2313
MGP Ingredients
MGPI
$377M
| $1.8M | ﹤0.01% |
35,200
-11,100
| -24% | -$579K |
|
2314
Kemper
KMPR
$1.62B
| $1.8M | ﹤0.01% |
46,600
-65,500
| -58% | -$2.57M |
|
|
AMED
2315
DELISTED
Amedisys
AMED
| $1.8M | ﹤0.01% |
28,618
+3,818
| +15% | +$222K |
|
2316
Greif
GEF
$4.98B
| $1.8M | ﹤0.01% |
32,200
-18,800
| -37% | -$1.06M |
|
2317
AMERISAFE
AMSF
$515M
| $1.79M | ﹤0.01% |
31,500
+2,600
| +9% | +$148K |
|
2318
NCR Voyix
VYX
$1.14B
| $1.79M | ﹤0.01% |
+71,557
| New | +$1.82M |
|
2319
Investar Holding Corp
ISTR
$426M
| $1.78M | ﹤0.01% |
77,735
+46,508
| +149% | +$1.04M |
|
2320
HUTCHMED
HCM
$2.1B
| $1.77M | ﹤0.01% |
76,000
+45,000
| +145% | +$924K |
|
2321
Ascent Industries
ACNT
$136M
| $1.77M | ﹤0.01% |
156,319
-8,481
| -5% | -$102K |
|
|
SNBR
2322
DELISTED
Sleep Number
SNBR
| $1.76M | ﹤0.01% |
+49,600
| New | +$1.48M |
|
2323
Stock Yards Bancorp
SYBT
$2.64B
| $1.76M | ﹤0.01% |
+45,150
| New | +$1.75M |
|
|
GPL
2324
DELISTED
Great Panther Mining Limited
GPL
| $1.75M | ﹤0.01% |
136,790
-5,150
| -4% | -$66.3K |
|
|
SBR
2325
Sabine Royalty Trust
SBR
$1.07B
| $1.75M | ﹤0.01% |
45,091
-1,750
| -4% | -$65.4K |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.